FILGRASTIM
CD20-Positive Neoplastic Cells Present
Fred Hutchinson Cancer Centerprotein_peptidePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the CD20-Positive Neoplastic Cells Present cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE M.D. Anderson Cancer Center | Phase 2 | CCC |
Evomela Fred Hutchinson Cancer Center | Phase 1 | CC |
Anti-Cd20 B9E9 Scfv-Streptavidin Fusion Protein Fred Hutchinson Cancer Center | Phase 1 | CC |
Cediranib Fred Hutchinson Cancer Center | Phase 1 | CC |
CARMUSTINE Fred Hutchinson Cancer Center | Phase 1 | CC |
Cytosin-Arabinosid Fred Hutchinson Cancer Center | Phase 1 | CC |
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →